Literature DB >> 30810698

Survival Differences in Women and Men After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.

Zahara Meghji1, Anita Nguyen1, Benish Fatima1, Jeffrey B Geske2, Rick A Nishimura2, Steve R Ommen2, Brian D Lahr3, Joseph A Dearani1, Hartzell V Schaff1.   

Abstract

Importance: Recent data indicate that women with hypertrophic cardiomyopathy (HCM) are older and more symptomatic at presentation and have worse clinical outcomes than men. However, to our knowledge, there are no large studies of the association of patient sex with outcomes after surgical myectomy. Objective: To analyze preoperative characteristics and overall survival of women and men undergoing septal myectomy for obstructive HCM. Design, Setting, and Participants: This retrospective, single-center study included the clinical data of adult patients who underwent septal myectomy from January 1961 through April 2016. Data analysis occurred from December 2017 to December 2018. Exposures: Septal myectomy. Main Outcomes and Measures: Survival.
Results: A total of 2506 adults were included; 1379 patients (55.0%) were men. At the time of surgery, women were older, with median (IQR) age of 59.5 (46.6-68.2) years vs 52.9 (42.9-62.7) years in men (P < .001). Women were more likely to have New York Heart Association class III or IV status at presentation (women, 1023 [90.8%]; men, 1169 [84.8%]; P < .001) and more severe obstructive physiology, as reflected in higher resting left ventricular outflow tract gradients (women, 67.0 [36.0-97.0] mm Hg; men, 50.0 [23.0-81.0] mm Hg; P < .001). Women also had a greater likelihood of having moderate or severe mitral regurgitation (606 [55.2%]) than men (581 [43.1%]; P < .001) and higher right ventricular systolic pressure (women, 36.0 [30.0-46.0] mm Hg; men, 33.0 [28.0-39.0] mm Hg; P < .001). The unadjusted overall survival was lower in women, corresponding to a median 3.9-year shorter survival than men (median [IQR] survival time: women, 18.2 [12.1-27.2] years; men, 22.1 [15.1-32.5] years; P < .001). In a multivariable Cox regression analysis, however, the association between sex and mortality was attenuated and not significant after controlling for other baseline variables (hazard ratio, 0.98 [95% CI, 0.76-1.26]; P = .86). Among the covariates in the model, older age at surgery (adjusted hazard ratio [aHR], 3.09 [95% CI, 2.12-4.52]; P < .001), higher body mass index (aHR, 1.22 [95% CI, 0.90-1.66]; P < .001), greater NYHA class (aHR, 2.31 [95% CI, 1.03-5.15]; P = .04), and presence of diabetes prior to surgery (aHR, 1.57 [95% CI, 1.10-2.24]; P = .01) were each independently associated with increased mortality. Operations performed later in the study period (2013 vs 2004) were associated with decreased mortality (aHR, 0.82 [95% CI, 0.55-1.22]; P = .001). Conclusions and Relevance: In this large cohort of surgical patients with obstructive HCM, we observed significant differences at clinical presentation between women and men, in that women were older and more symptomatic. However, after adjustment for important baseline prognostic factors, there was no survival difference after septal myectomy by sex. Improved care of women with obstructive HCM should focus on early identification of disease and prompt surgical referral of appropriate patients who do not respond to medical treatment.

Entities:  

Mesh:

Year:  2019        PMID: 30810698      PMCID: PMC6439557          DOI: 10.1001/jamacardio.2019.0084

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  34 in total

1.  New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome.

Authors:  K H Humphries; C R Kerr; S J Connolly; G Klein; J A Boone; M Green; R Sheldon; M Talajic; P Dorian; D Newman
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

2.  Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.

Authors:  William A Zoghbi; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Carol D Kraft; Robert A Levine; Petros Nihoyannopoulos; Catherine M Otto; Miguel A Quinones; Harry Rakowski; William J Stewart; Alan Waggoner; Neil J Weissman
Journal:  J Am Soc Echocardiogr       Date:  2003-07       Impact factor: 5.251

3.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

4.  Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Authors:  Shelley Shapiro; Glenna L Traiger; Michelle Turner; Michael D McGoon; Prieya Wason; Robyn J Barst
Journal:  Chest       Date:  2011-07-14       Impact factor: 9.410

5.  Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy.

Authors:  Barry J Maron
Journal:  Circulation       Date:  2007-07-10       Impact factor: 29.690

6.  Why we need more septal myectomy surgeons: An emerging recognition.

Authors:  Barry J Maron; Joseph A Dearani; Martin S Maron; Steve R Ommen; Hassan Rastegar; Rick A Nishimura; Daniel G Swistel; Mark V Sherrid; Anthony Ralph-Edwards; Harry Rakowski; Nicholas G Smedira; Ethan J Rowin; Milind Y Desai; Harry M Lever; Paolo Spirito; Paolo Ferrazzi; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2017-02-01       Impact factor: 5.209

7.  Editor's Choice-Sex differences in young patients with acute myocardial infarction: A VIRGO study analysis.

Authors:  Emily M Bucholz; Kelly M Strait; Rachel P Dreyer; Stacy T Lindau; Gail D'Onofrio; Mary Geda; Erica S Spatz; John F Beltrame; Judith H Lichtman; Nancy P Lorenze; Hector Bueno; Harlan M Krumholz
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2016-08-02

8.  National study of physician awareness and adherence to cardiovascular disease prevention guidelines.

Authors:  Lori Mosca; Allison H Linfante; Emelia J Benjamin; Kathy Berra; Sharonne N Hayes; Brian W Walsh; Rosalind P Fabunmi; Johnny Kwan; Thomas Mills; Susan Lee Simpson
Journal:  Circulation       Date:  2005-02-01       Impact factor: 29.690

9.  Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events.

Authors:  S Dey; M D Flather; G Devlin; D Brieger; E P Gurfinkel; P G Steg; G Fitzgerald; E A Jackson; K A Eagle
Journal:  Heart       Date:  2008-05-07       Impact factor: 5.994

10.  Women with hypertrophic cardiomyopathy have worse survival.

Authors:  Jeffrey B Geske; Kevin C Ong; Konstantinos C Siontis; Virginia B Hebl; Michael J Ackerman; David O Hodge; Virginia M Miller; Rick A Nishimura; Jae K Oh; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen
Journal:  Eur Heart J       Date:  2017-12-07       Impact factor: 29.983

View more
  16 in total

Review 1.  Targeted Medical Therapies for Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Maria Grazia De Gregorio; Mattia Zampieri; Elisa Fedele; Alessia Tomberli; Chiara Chiriatti; Alberto Marchi; Iacopo Olivotto
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

2.  Gender-Related Differences in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Angkawipa Trongtorsak; Natchaya Polpichai; Sittinun Thangjui; Jakrin Kewcharoen; Ratdanai Yodsuwan; Amrit Devkota; Harvey J Friedman; Alfonso Q Estrada
Journal:  Pulse (Basel)       Date:  2021-08-02

3.  Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

Authors:  You-Zhou Chen; Xing-Shan Zhao; Jian-Song Yuan; Yan Zhang; Wei Liu; Shu-Bin Qiao
Journal:  Biol Sex Differ       Date:  2022-07-07       Impact factor: 8.811

Review 4.  Hypertrophic cardiomyopathy.

Authors:  Murillo de Oliveira Antunes; Thiago Luis Scudeler
Journal:  Int J Cardiol Heart Vasc       Date:  2020-03-25

5.  Survival Differences in Men and Women With Primary Malignant Cardiac Tumor: An Analysis Using the Surveillance, Epidemiology and End Results (SEER) Database From 1973 to 2015.

Authors:  Daniel Antwi-Amoabeng; Zahara Meghji; Samarthkumar Thakkar; Mark B Ulanja; Mohamed Taha; Devina Adalja; Jaafar Al-Khafaji; Nageshwara Gullapalli; Bryce D Beutler; Killian Boampong-Konam; Rajkumar Doshi
Journal:  J Am Heart Assoc       Date:  2020-05-10       Impact factor: 5.501

6.  Angiotensinogen M235T polymorphism and susceptibility to hypertrophic cardiomyopathy in Asian population: A meta analysis.

Authors:  Zhen Zhen; Lu Gao; Qin Wang; Xi Chen; Jia Na; Xiwei Xu; Yue Yuan
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

7.  Sex differences in the prognosis of patients with hypertrophic cardiomyopathy.

Authors:  Minkwan Kim; Bongsung Kim; You-Jung Choi; Hyun-Jung Lee; Heesun Lee; Jun-Bean Park; Seung-Pyo Lee; Kyung-Do Han; Yong-Jin Kim; Hyung-Kwan Kim
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

8.  Sex, Survival, and Cardiomyopathy: Differences Between Men and Women With Hypertrophic Cardiomyopathy.

Authors:  Konstantinos C Siontis; Steve R Ommen; Jeffrey B Geske
Journal:  J Am Heart Assoc       Date:  2019-10-30       Impact factor: 5.501

9.  Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Martin S Maron; Sophie Wells; Parth P Patel; Benjamin C Koethe; Barry J Maron
Journal:  J Am Heart Assoc       Date:  2019-10-30       Impact factor: 5.501

10.  Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.

Authors:  Peter Marstrand; Larry Han; Sharlene M Day; Iacopo Olivotto; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Samuel G Wittekind; Adam Helms; Sara Saberi; Daniel Jacoby; James S Ware; Steven D Colan; Christopher Semsarian; Jodie Ingles; Neal K Lakdawala; Carolyn Y Ho
Journal:  Circulation       Date:  2020-03-31       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.